MRC1 and acute myeloid leukemia: This is in line with Yang et al. (2017)’s results, showing decreased probability of survival in AML patients with high CD163 transcript levels (as well as CD206, CD163 also used to define M2-like Mφs), as compared to patients with lower CD163 levels.